Destiny Pharma announces research collaboration with Aston University to investigate new XF-platform drug candidates

Research to investigate potential antimicrobial candidates against biofilms

July 17, 2018
Destiny Pharma plc

Brighton, United Kingdom – 17 July 2018 – Destiny Pharma (AIM: DEST), a clinical stage biotechnology company focused on the development of novel antimicrobial drugs, which address the global problem of antimicrobial resistance (AMR), today announces it has signed a three-year research collaboration agreement with Aston University. The research is intended to examine novel compounds from the Company’s XF-platform and assess their potential to prevent, control and eradicate dangerous bacteria and biofilms.

Full Press Release available: